Comparing two drug combinations for newly diagnosed follicular lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two drug combinations for people newly diagnosed with follicular lymphoma. One group gets zanubrutinib plus lenalidomide, and the other gets lenalidomide plus rituximab. The goal is to see which combination works better with acceptable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a common type of follicular lymphoma (grades 1–3a) and have not had any previous treatment for it.
- You need treatment now because of symptoms or tumor burden (according to standard criteria).
- You have at least one measurable tumor that can be seen on a scan.
- You are fit enough (able to do daily activities with some help) and have adequate organ function.
- You are willing to use effective contraception during treatment and for 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This study is testing a combination of three drugs—zanubrutinib, obinutuzumab, and lenalidomide—as a first treatment for people with a certain type of follicular lymphoma that is considered high-risk. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
This trial tests whether a new drug, odronextamab, combined with lenalidomide works better than the current standard, rituximab combined with lenalidomide, for people whose follicular or marginal zone lymphoma has come back or not responded to prior treatment. It aims to see which combo is safer and more effective.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
Hear when a new Follicular Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.